专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明专利

SI3068421T1 Selektivne spojine PYY in njihova uporaba 未知
公开(公告)号：SI3068421T1
公开(公告)日：2019-08-30
申请号：SI201431251
申请日：2014-11-13
申请人： NOVO NORDISK AS
发明人： OSTERGAARD SOREN , FRIEBOES KILIAN WALDEMAR CONDE , WIECZOREK BIRGIT , THOMSEN JENS KAALBY , WULFF BIRGITTE SCHJELLERUP , JESSEN CARSTEN
IPC分类号： A61K38/00 , C07K14/00

62. 发明专利

RS59026B1 SELEKTIVNA PYY JEDINJENJA I NJIHOVA UPOTREBA 未知
公开(公告)号：RS59026B1
公开(公告)日：2019-08-30
申请号：RSP20190792
申请日：2014-11-13
申请人： NOVO NORDISK AS
发明人： ØSTERGAARD SØREN , FRIEBOES KILIAN WALDEMAR CONDE , WIECZOREK BIRGIT , THOMSEN JENS KAALBY , WULFF BIRGITTE SCHJELLERUP , JESSEN CARSTEN
IPC分类号： A61K38/22 , C07K14/575

63. 发明专利

DK3236991T3 FGF21-DERIVATER OG ANVENDELSER DERAF 未知
公开(公告)号：DK3236991T3
公开(公告)日：2019-08-26
申请号：DK15817847
申请日：2015-12-22
申请人： NOVO NORDISK AS
发明人： WIECZOREK BIRGIT , ANDERSEN BIRGITTE , OLSEN JØRGEN , SASS-ØRUM KRISTIAN , TAGMOSE TINA MØLLER
IPC分类号： A61K38/00 , A61K38/18 , A61K47/54 , C07K14/50

64. 发明专利

ES2692495T3 Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos 未知
公开(公告)号：ES2692495T3
公开(公告)日：2018-12-03
申请号：ES10701661
申请日：2010-01-22
申请人： NOVO NORDISK AS
发明人： TAGMOSE TINA MØLLER , GARIBAY PATRICK WILLIAM , ANDERSEN BIRGITTE , WANG JISHU , CONDE FRIEBOES KILIAN WALDEMAR , BAK-JENSEN KRISTIAN SASS , THØGERSEN HENNING , WÖLDIKE HELLE , NIELSEN PETER KRESTEN , SLAABY RITA , ZHANG XUJIA , WIECZOREK BIRGIT
IPC分类号： A61K38/18 , A61K47/54 , A61P3/04 , C07K14/50
摘要： Un derivado de un FGF21 que tiene un aglutinante de albúmina de la fórmula A-B-C-D-E- unido covalentemente, en donde A-B-C-D-E- se selecciona a partir de las siguientes fórmulas (1)-(8):**Fórmula** o una sal farmacéuticamente aceptable de cualquiera de los derivados correspondientes.

65. 发明专利

MA43858A ANALOGUES D'EGF(A) AVEC SUBSTITUANTS ACIDES GRAS 未知
公开(公告)号：MA43858A
公开(公告)日：2018-11-21
申请号：MA43858
申请日：2017-01-13
申请人： NOVO NORDISK AS
发明人： CHEN JIANHE , GARIBAY PATRICK WILLIAM , KODRA JÁNOS TIBOR , LAU JESPER F , LINDEROTH LARS , RASMUSSEN SALKA ELBØL , THØGERSEN HENNING , WIECZOREK BIRGIT
IPC分类号： A61K38/17 , C07K14/705

66. 发明专利

AU2017207862A1 EGF(A) analogues with fatty acid substituents 未知
公开(公告)号：AU2017207862A1
公开(公告)日：2018-07-05
申请号：AU2017207862
申请日：2017-01-13
申请人： NOVO NORDISK AS
发明人： CHEN JIANHE , LAU JESPER F , KODRA JÁNOS TIBOR , WIECZOREK BIRGIT , LINDEROTH LARS , THØGERSEN HENNING , RASMUSSEN SALKA ELBØL , GARIBAY PATRICK WILLIAM
IPC分类号： C07K14/705 , A61K38/17
摘要： The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293- 332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.

67. 发明专利

CA3010756A1 EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS 未知
公开(公告)号：CA3010756A1
公开(公告)日：2017-07-20
申请号：CA3010756
申请日：2017-01-13
申请人： NOVO NORDISK AS
发明人： CHEN JIANHE , LAU JESPER F , KODRA JANOS TIBOR , WIECZOREK BIRGIT , LINDEROTH LARS , THOGERSEN HENNING , RASMUSSEN SALKA ELBOL , GARIBAY PATRICK WILLIAM
IPC分类号： C07K14/705 , A61K38/17
摘要： The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293- 332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.

68. 发明专利

AU2015371056A1 FGF21 derivatives and uses thereof 未知
公开(公告)号：AU2015371056A1
公开(公告)日：2017-06-15
申请号：AU2015371056
申请日：2015-12-22
申请人： NOVO NORDISK AS
发明人： WIECZOREK BIRGIT , TAGMOSE TINA MOLLER , SASS-ORUM KRISTIAN , ANDERSEN BIRGITTE , OLSEN JORGEN
IPC分类号： C07K14/50 , A61K38/18
摘要： The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.

69. 发明专利

AU2010207721B2 FGF21 derivatives with albumin binder A-B-C-D-E- and their use 未知
公开(公告)号：AU2010207721B2
公开(公告)日：2015-03-26
申请号：AU2010207721
申请日：2010-01-22
申请人： NOVO NORDISK AS
发明人： TAGMOSE TINA MOLLER , GARIBAY PATRICK WILLIAM , ANDERSEN BIRGITTE , WANG JISHU , CONDE FRIEBOES KILIAN WALDEMAR , BAK-JENSEN KRISTIAN SASS , THOGERSEN HENNING , WOLDIKE HELLE , NIELSEN PETER KRESTEN , SLAABY RITA , ZHANG XUJIA , WIECZOREK BIRGIT
IPC分类号： A61K38/18 , A61K47/48 , A61P3/04
摘要： The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B- C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.

70. 发明专利

ZA201307119B DOUBLE-ACYLATED GLP-1 DERIVATIVES 未知
公开(公告)号：ZA201307119B
公开(公告)日：2014-05-28
申请号：ZA201307119
申请日：2013-09-20
申请人： NOVO NORDISK AS
发明人： WIECZOREK BIRGIT , KRUSE THOMAS , KOFOED JACOB , SPETZLER JANE , LINDEROTH LARS
IPC分类号： A01N20060101 , A01P20060101 , A61K20060101 , C07K20060101
摘要： The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1 (7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1 (7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1 (7-37); wherein the first K residue is designated K 27 , and the second K residue is designated K T ; which derivative comprises two albumin binding moieties attached to K 27 and K T , respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC-(CH 2 ) x -CO- and HOOC-C 6 H 4 -O-(CH 2 ) y -CO-; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula -NH-(CH 2 ) 2 -(O-(CH 2 ) 2 ) k -O-(CH 2 ) n -CO-, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel GLP-1 analogues. The derivatives are suitable for oral administration.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式